Gastric Cancer Trial Now Open at Tasman Health Care

Tasman Health Care is pleased to announce that recruitment is open for the CA209-649 study. This is a study for patients with gastric or gastroesophageal junction cancer and compares immunotherapy agents nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving chemotherapy alone.

Further information can be found at https:/